TCL-1 gene and protein and related methods and compositions
AssigneeThomas Jefferson University
InventorsGiandomenico Russo, Carlo Croce
Life of this patent
Estimating the term…
Abstract
The present invention relates to nucleotide sequences of TCL-1 genes and amino acid sequences of their encoded proteins, as well as derivatives and analogs thereof, and antibodies thereto. The TCL-1 gene sequence is preferentially expressed early in T and B lymphocyte differentiation. The present invention further relates to the use of TCL-1 genes and their encoded proteins as diagnostic and therapeutic reagents for the detection and treatment of disease states associated with chromosomal abnormalities.
Claims66
An isolated nucleic acid comprising a nucleotide sequence encoding a TCL-1 protein, wherein the nucleotide sequence is a cDNA sequence.
2-4. (canceled)
An isolated TCL-1 protein.
6-10. (canceled)
An antisense molecule comprising a nucleotide sequence complementary to at least a part of the coding sequence of a TCL-1 protein, which is hybridizable to a TCL-1 mRNA.
12-13. (canceled)
An antibody which binds to an epitope of a TCL-1 protein.
17-21. (canceled)
A method for detecting a target sequence indicative of a chromosome 14 abnormality in a sample, comprising the steps of:
- (a) amplifying the target sequence in the sample using a first primer of 18 to 25 nucleotides complementary to the nucleotide sequence of SEQ ID NO:1, and a second primer complementary to a region telomeric or centromeric to the TCL-1 gene;
- and
- (b) detecting any resulting amplified target sequence in which the presence of the amplified target sequence is indicative of the abnormality.
23-30. (canceled)
32-36. (canceled)
41-45. (canceled)
A method for treating a disease state associated with a chromosome 14 abnormality in a mammal suffering from a disease state associated with a chromosome 14 abnormality, comprising administering a therapeutically effective amount of a TCL-1 antisense molecule to the mammal.
47-49. (canceled)
(canceled)
An isolated oligonucleotide having in the range of 15-25 nucleotides which is hybridizable to a DNA molecule, said molecule comprising the sequence shown in SEQ ID NO:3 or its complement.
63-64. (canceled)
An isolated oligonucleotide having in the range of 15-25 nucleotides which is hybridizable to a DNA molecule, said molecule comprising the sequence shown in SEQ ID NO:5 or its complement.
The method of claim 94, wherein the analogous sample is taken from the same patient before therapy is initiated.
Dependencies are inferred from the claim text.